{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:54:54Z","timestamp":1791122094340,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ctrv.2014.02.008","type":"journal-article","created":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T05:30:38Z","timestamp":1394775038000},"page":"770-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"title":["HER2 aberrations in cancer: Implications for therapy"],"prefix":"10.1016","volume":"40","author":[{"given":"Min","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2014.02.008_b0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(03)00048-0","article-title":"The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors","volume":"11","author":"Garrett","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.ctrv.2014.02.008_b0015","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Graus-Porta","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.ctrv.2014.02.008_b0020","first-page":"1813","article-title":"Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas","volume":"10","author":"Alimandi","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2014.02.008_b0025","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Holbro","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2014.02.008_b0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1126\/science.2885917","article-title":"ErbB-2 is a potent oncogene when overexpressed in NIH\/3T3 cells","volume":"237","author":"Di Fiore","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2014.02.008_b0035","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1073\/pnas.84.20.7159","article-title":"Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells","volume":"84","author":"Hudziak","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2014.02.008_b0040","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ncb0901-785","article-title":"ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini","volume":"3","author":"Muthuswamy","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc2127","article-title":"Insights from transgenic mouse models of ERBB2-induced breast cancer","volume":"7","author":"Ursini-Siegel","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0050","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2014.02.008_b0055","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2014.02.008_b0060","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2014.02.008_b0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2014.02.008_b0070","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2014.02.008_b0075","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2014.02.008_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","article-title":"HER2-positive gastric cancer","volume":"17","author":"Boku","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0665","article-title":"Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection","author":"Oh","year":"2013","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0090","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3748\/wjg.v19.i14.2171","article-title":"Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer","volume":"19","author":"He","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0095","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2013.48.9070","article-title":"Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab","volume":"31","author":"Gomez-Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0100","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/JTO.0b013e31827ce38e","article-title":"Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment","volume":"8","author":"Falchook","year":"2013","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0105","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc060020","article-title":"HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer","volume":"354","author":"Cappuzzo","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2014.02.008_b0110","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.2012.43.4902","article-title":"HER2 mutations in non-small-cell lung cancer can be continually targeted","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0670","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/hed.23429","article-title":"Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment","volume":"36","author":"Falchook","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2014.02.008_b0120","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0125","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2014.02.008_b0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2013 mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2014.02.008_b0135","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study","volume":"30","author":"Blackwell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0140","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2014.02.008_b0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2014.02.008_b0150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0675","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0160","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2014.02.008_b0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2012.01.008","article-title":"Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2\/neu","volume":"76","author":"De Greve","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0170","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/cncr.26574","article-title":"Clinical trial results of the HER-2\/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US military cancer institute clinical trials group study I-01 and I-02","volume":"118","author":"Mittendorf","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0180","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0185","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2014.02.008_b0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/1078-0432.CCR-05-0976","article-title":"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas","volume":"12","author":"Lee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0195","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clinical Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0200","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2014.02.008_b0205","unstructured":"<http:\/\/www.clinicaltrials.gov\/ct2\/results?term=HER2&recr=Open&rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=, accessed on 02\/14\/2014> [accessed on 02\/14\/2014]."},{"key":"10.1016\/j.ctrv.2014.02.008_b0210","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1200\/JCO.2012.42.3061","article-title":"Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma","volume":"30","author":"Law","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-1","article-title":"Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?","volume":"9","author":"Kavanagh","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1471-2407-6-123","article-title":"HER 2\/neu protein expression in colorectal cancer","volume":"6","author":"Schuell","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0225","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/1471-2407-11-277","article-title":"Clinicopathological and prognostic significance of HER-2\/neu and VEGF expression in colon carcinomas","volume":"11","author":"Li","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0230","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4137\/CMO.S10811","article-title":"Cytoplasmic overexpression of HER2: a key factor in colorectal cancer","volume":"7","author":"Blok","year":"2013","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0235","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2014.02.008_b0240","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1081\/CNV-200039645","article-title":"Low overexpression of HER-2\/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial","volume":"22","author":"Ramanathan","year":"2004","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2014.02.008_b0245","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s11605-012-1979-2","article-title":"Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer","volume":"16","author":"Chan","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ctrv.2014.02.008_b0250","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/1078-0432.CCR-11-2272","article-title":"Association of HER2\/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas","volume":"18","author":"Yoon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0255","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1186\/1471-2407-12-569","article-title":"Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas","volume":"12","author":"Gonzaga","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0260","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10637-010-9541-0","article-title":"Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors","volume":"30","author":"Galsky","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2014.02.008_b0265","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.lungcan.2011.01.014","article-title":"Prognostic and predictive implications of HER2\/ERBB2\/neu gene mutations in lung cancers","volume":"74","author":"Tomizawa","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/j.seminoncol.2003.12.018","article-title":"The role of HER2\/neu expression and trastuzumab in non-small cell lung cancer","volume":"31","author":"Hirsch","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0275","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.bjc.6601252","article-title":"The role of HER-2\/neu expression on the survival of patients with lung cancer: a systematic review of the literature","volume":"89","author":"Meert","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0280","first-page":"5238","article-title":"HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin","volume":"9","author":"Heinmoller","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0285","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2014.02.008_b0290","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazieres","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0295","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","article-title":"Somatic mutations of the HER2 kinase domain in lung adenocarcinomas","volume":"65","author":"Shigematsu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0300","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.2006.09.4300","article-title":"Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive\/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial","volume":"25","author":"Cappuzzo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0305","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2004.04.105","article-title":"Eastern cooperative oncology group S. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? focus on eastern cooperative oncology group study 2598","volume":"22","author":"Langer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0310","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/mdh031","article-title":"Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","volume":"15","author":"Gatzemeier","year":"2004","journal-title":"Annals Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0315","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ctrv.2006.01.001","article-title":"Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer","volume":"32","author":"Serrano-Olvera","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2014.02.008_b0320","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2009.02.009","article-title":"Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a gynecologic oncology group study","volume":"113","author":"Farley","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0325","doi-asserted-by":"crossref","first-page":"e1138","DOI":"10.1371\/journal.pone.0001138","article-title":"HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients","volume":"2","author":"Tuefferd","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2014.02.008_b0330","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology"},{"key":"10.1016\/j.ctrv.2014.02.008_b0335","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0340","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4088","article-title":"Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas","volume":"229","author":"Anglesio","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0345","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1078-0432.CCR-10-1688","article-title":"Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas","volume":"17","author":"Tan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0350","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1245\/s10434-011-1572-z","article-title":"Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer","volume":"18","author":"Lin","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0355","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00109-006-0054-4","article-title":"Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma","volume":"84","author":"Lassus","year":"2006","journal-title":"J Mol Med"},{"key":"10.1016\/j.ctrv.2014.02.008_b0360","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0365","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1349-7006.2009.01176.x","article-title":"HER2 overexpression correlates with survival after curative resection of pancreatic cancer","volume":"100","author":"Komoto","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2014.02.008_b0370","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1200\/JCO.2004.05.142","article-title":"Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma","volume":"22","author":"Stoecklein","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0375","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/gm482","article-title":"Clinical and molecular characterization of HER2 amplified-pancreatic cancer","volume":"5","author":"Chou","year":"2013","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2014.02.008_b0380","doi-asserted-by":"crossref","first-page":"e12653","DOI":"10.1371\/journal.pone.0012653","article-title":"Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas","volume":"5","author":"Corbo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2014.02.008_b0385","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/bjc.2012.18","article-title":"Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer","volume":"106","author":"Harder","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0680","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archotol.1991.01870150075010","article-title":"Primary parotid malignancies. A clinical and pathologic review","volume":"117","author":"Kane","year":"1991","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ctrv.2014.02.008_b0395","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1078-0432.CCR-12-1842","article-title":"Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment","volume":"19","author":"Nardi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0400","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/1078-0432.CCR-09-0238","article-title":"Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance","volume":"16","author":"Williams","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0405","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1078\/0344-0338-00136","article-title":"Salivary duct carcinoma \u2013 a highly aggressive salivary gland tumor with HER-2\/neu oncoprotein overexpression","volume":"197","author":"Skalova","year":"2001","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ctrv.2014.02.008_b0410","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hed.20614","article-title":"Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy","volume":"29","author":"Nabili","year":"2007","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2014.02.008_b0415","doi-asserted-by":"crossref","first-page":"463","DOI":"10.18632\/oncotarget.886","article-title":"A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): implications for inhibition of the IGF-1R signal","volume":"4","author":"Janku","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2014.02.008_b0420","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0425","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"Lae","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0430","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2014.02.008_b0435","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/modpathol.2011.69","article-title":"HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization","volume":"24","author":"Ching","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0440","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0445","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2407-4-59","article-title":"HER2 expression in cervical cancer as a potential therapeutic target","volume":"4","author":"Chavez-Blanco","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0450","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000195539","article-title":"Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer","volume":"76","author":"Perez-Regadera","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2014.02.008_b0455","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1600-0463.2009.02531.x","article-title":"HER2\/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens","volume":"117","author":"Lesnikova","year":"2009","journal-title":"APMIS"},{"key":"10.1016\/j.ctrv.2014.02.008_b0460","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0465","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3748\/wjg.15.4511","article-title":"EGFR and HER2 expression in advanced biliary tract cancer","volume":"15","author":"Harder","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0685","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0475","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0480","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0485","first-page":"2219","article-title":"Clinical relevance of HER-2\/neu expression in germ-cell testicular tumors","volume":"24","author":"Mandoky","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0490","first-page":"26","article-title":"Clinical relevance of HER-2\/neu overexpression in patients with testicular nonseminomatous germ cell tumor","volume":"7","author":"Ghavamnasiri","year":"2010","journal-title":"Urol J"},{"key":"10.1016\/j.ctrv.2014.02.008_b0495","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/jcp.55.9.656","article-title":"HER-2\/neu expression in germ cell tumours","volume":"55","author":"Soule","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0500","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-007-9424-1","article-title":"Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma","volume":"85","author":"Mineo","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0505","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.COC.0000020922.66984.E7","article-title":"Role of Her-2\/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme","volume":"26","author":"Koka","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0510","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/bjc.2011.237","article-title":"Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck","volume":"105","author":"Del Campo","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0515","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/jcp.2004.023556","article-title":"Overexpression\/amplification of HER-2\/neu is uncommon in hepatocellular carcinoma","volume":"58","author":"Xian","year":"2005","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0520","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1471-2407-6-278","article-title":"A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma","volume":"6","author":"Bekaii-Saab","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0525","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.cmr.0000130874.33504.2f","article-title":"Her2\/neu is not a commonly expressed therapeutic target in melanoma \u2013 a large cohort tissue microarray study","volume":"14","author":"Kluger","year":"2004","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0530","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jso.10297","article-title":"Absence of HER2 overexpression in metastatic malignant melanoma","volume":"84","author":"Inman","year":"2003","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0535","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.humpath.2010.09.016","article-title":"Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma","volume":"42","author":"Baumhoer","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0540","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.juro.2010.04.077","article-title":"Her-2\/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis","volume":"184","author":"Neto","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0545","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-09-2546","article-title":"Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer","volume":"16","author":"Minner","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0550","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3892\/ol.2012.727","article-title":"HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue","volume":"4","author":"Wang","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2014.02.008_b0555","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1245\/s10434-011-2184-3","article-title":"Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2\/neu, and survivin","volume":"19","author":"da Cunha","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0560","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0046-8177(03)00238-7","article-title":"Molecular and immunohistochemical analysis of HER2\/neu oncogene in synovial sarcoma","volume":"34","author":"Nuciforo","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0565","unstructured":"FDA. <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125409s051lbl.pdf 2013>."},{"key":"10.1016\/j.ctrv.2014.02.008_b0570","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","article-title":"Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy","volume":"28","author":"Baselga","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0690","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1158\/1078-0432.CCR-13-0358","article-title":"Dual targeting of HER2-positive cancer with trastuzumab-emtansine (T-DM1) and pertuzumab: critical role for neuregulin blockade in anti-tumor response to combination therapy","volume":"20","author":"Lewis Phillips","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0580","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3816\/CBC.2009.n.003","article-title":"A phase I\/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach","volume":"9","author":"Britten","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0585","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","article-title":"Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy","volume":"29","author":"Morrow","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0590","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cllc.2012.03.004","article-title":"A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer","volume":"13","author":"Felip","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.02.008_b0595","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-011-1918-z","article-title":"A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer","volume":"134","author":"Rugo","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2014.02.008_b0600","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1634\/theoncologist.2011-0344","article-title":"Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer","volume":"17","author":"Martin","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2014.02.008_b0605","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10549-011-1850-2","article-title":"A phase I\/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer","volume":"131","author":"Somlo","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2014.02.008_b0610","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2009.22.3354","article-title":"Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer","volume":"28","author":"Makhija","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.02.008_b0615","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-012-2341-9","article-title":"Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen","volume":"137","author":"Yardley","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2014.02.008_b0620","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0625","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0630","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/bcr3069","article-title":"Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties","volume":"13","author":"Nordstrom","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0695","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1158\/0008-5472.CAN-07-0538","article-title":"A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib","volume":"67","author":"de La Motte Rouge","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0640","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1158\/0008-5472.CAN-09-3360","article-title":"CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity","volume":"70","author":"Lai","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0645","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1158\/0008-5472.CAN-13-1198","article-title":"An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin","volume":"73","author":"Garner","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.02.008_b0650","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1158\/1535-7163.MCT-11-0671","article-title":"(212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease","volume":"11","author":"Yong","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2014.02.008_b0655","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1172\/JCI42672","article-title":"An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2014.02.008_b0660","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/cgt.2011.83","article-title":"Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma","volume":"19","author":"Rainusso","year":"2012","journal-title":"Cancer Gene Ther"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T12:59:34Z","timestamp":1565269174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":132,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0305737214000437"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.02.008","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 aberrations in cancer: Implications for therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}